Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print   

Thursday 03 February, 2022

C4X Discovery

Grant of Options and Directors Dealing

RNS Number : 5237A
C4X Discovery Holdings PLC
03 February 2022
 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Grant of Options and Directors Dealing

 

3 February 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that a total of 3,880,000 options over ordinary shares of the Company were awarded pursuant to the 2014 Share Option Plan to certain employees, which includes 200,000 options each to Dr Clive Dix, Chief Executive Officer, Brad Hoy, Chief Financial Officer and Bhavna Hunjan, Chief Business Officer as set out below.

 

Director

Position

Number of share options awarded

Option exercise price per share (pence)

Total number of options held

Dr Clive Dix

Chief Executive Officer

200,000

36

845,000

Brad Hoy

Chief Financial Officer

200,000

36

1,000,000

Bhavna Hunjan

Chief Business Officer

200,000

36

855,556

 

The options have an exercise price of 36 pence, being the average 5-day VWAP of the ordinary shares to the 1 February 2022.  The options can be exercised at any time between three and 10 years of them being granted.

 

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name(s)

 

Dr Clive Dix

2

Reason for the notification


a)


Position/status

 

Chief Executive Officer, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

213800UHNL82E323O870

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan

 

ISIN GB00BQQ2RV18

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

36p

200,000

 

d)

Aggregated information

 

 

e)

Date of the transaction

 

1 February 2022

f)

Place of the transaction

London Stock Exchange - AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Brad Hoy

2

Reason for the notification


a)


Position/status

 

Chief Financial Officer, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

213800UHNL82E323O870

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan

 

ISIN GB00BQQ2RV18

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

36p

200,000

 

d)

Aggregated information

 

 

e)

Date of the transaction

 

1 February 2022

f)

Place of the transaction

 

London Stock Exchange - AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Bhavna Hunjan

2

Reason for the notification


a)


Position/status

 

Chief Business Officer, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

213800UHNL82E323O870

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan

 

ISIN GB00BQQ2RV18

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

36p

200,000

 

d)

Aggregated information

 

 

e)

Date of the transaction

 

1 February 2022

f)

Place of the transaction

London Stock Exchange - AIM

 

- Ends -

 

Contacts

 

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

Rupert Dearden (Corporate Broking)




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUURBRUSUURAR

a d v e r t i s e m e n t